Standard
Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis : a population-based study from DANBIO and the Danish Multiple Sclerosis Registry. / Dreyer, L; Magyari, M; Laursen, B.; Cordtz, R; Sellebjerg, F; Locht, H.
I:
Annals of the Rheumatic Diseases, Bind 75, Nr. 4, 04.2016, s. 785-6.
Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
Harvard
Dreyer, L, Magyari, M, Laursen, B, Cordtz, R
, Sellebjerg, F & Locht, H 2016, '
Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry',
Annals of the Rheumatic Diseases, bind 75, nr. 4, s. 785-6.
https://doi.org/10.1136/annrheumdis-2015-208490APA
Dreyer, L., Magyari, M., Laursen, B., Cordtz, R.
, Sellebjerg, F., & Locht, H. (2016).
Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry.
Annals of the Rheumatic Diseases,
75(4), 785-6.
https://doi.org/10.1136/annrheumdis-2015-208490Vancouver
Dreyer L, Magyari M, Laursen B, Cordtz R
, Sellebjerg F, Locht H.
Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry.
Annals of the Rheumatic Diseases. 2016 apr.;75(4):785-6.
https://doi.org/10.1136/annrheumdis-2015-208490Author
Dreyer, L ; Magyari, M ; Laursen, B. ; Cordtz, R ; Sellebjerg, F ; Locht, H. / Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis : a population-based study from DANBIO and the Danish Multiple Sclerosis Registry. I: Annals of the Rheumatic Diseases. 2016 ; Bind 75, Nr. 4. s. 785-6.
Bibtex
@article{971920ee231945f5b72fc6b177ca5538,
title = "Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry",
keywords = "Adult, Aged, Antirheumatic Agents, Arthritis, Psoriatic, Arthritis, Rheumatoid, Denmark, Female, Humans, Incidence, Male, Middle Aged, Multiple Sclerosis, Registries, Risk Factors, Spondylitis, Ankylosing, Tumor Necrosis Factor-alpha, Letter, Research Support, Non-U.S. Gov't",
author = "L Dreyer and M Magyari and B. Laursen and R Cordtz and F Sellebjerg and H. Locht",
year = "2016",
month = apr,
doi = "10.1136/annrheumdis-2015-208490",
language = "English",
volume = "75",
pages = "785--6",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "B M J Group",
number = "4",
}
RIS
TY - JOUR
T1 - Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis
T2 - a population-based study from DANBIO and the Danish Multiple Sclerosis Registry
AU - Dreyer, L
AU - Magyari, M
AU - Laursen, B.
AU - Cordtz, R
AU - Sellebjerg, F
AU - Locht, H.
PY - 2016/4
Y1 - 2016/4
KW - Adult
KW - Aged
KW - Antirheumatic Agents
KW - Arthritis, Psoriatic
KW - Arthritis, Rheumatoid
KW - Denmark
KW - Female
KW - Humans
KW - Incidence
KW - Male
KW - Middle Aged
KW - Multiple Sclerosis
KW - Registries
KW - Risk Factors
KW - Spondylitis, Ankylosing
KW - Tumor Necrosis Factor-alpha
KW - Letter
KW - Research Support, Non-U.S. Gov't
U2 - 10.1136/annrheumdis-2015-208490
DO - 10.1136/annrheumdis-2015-208490
M3 - Letter
C2 - 26698850
VL - 75
SP - 785
EP - 786
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
SN - 0003-4967
IS - 4
ER -
